Scoparone inhibits pancreatic cancer through PI3K/Akt signaling pathway

Figure 5 Scoparone inhibits the PI3K/Akt signaling pathway. A-D: Scoparone inhibits the PI3K/Akt signaling pathway in Capan-2 (A and B) and SW1990 (C and D) cells. Scoparone treatment did not decrease the total expression of PI3K and Akt, but decreased p-Akt expression; E and F: Scoparone decreases the expression of AKT1 (E) and increases the expression of MAPK8 (F) as shown by quantitative reverse transcription polymerase chain reaction; G: Images of nude mice and xenograft tumors after treatment with 200 μmol/L scoparone compared with the control group; H: Tumor volume at different time points after treatment with 200 μmol/L scoparone compared with the control group; I: Tumor weight after treatment with 200 μmol/L scoparone compared with the control group; J: Immunohistochemistry (IHC) was performed on xenograft tumors to evaluate PCNA and Ki67 expression. Shown are representative images; K and L: The number of PCNA or Ki67 positive cells were counted from PCNA IHC (K) and Ki67 IHC (L), and decreased PCNA and Ki67 were observed after treatment with scoparone. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001, ^dP < 0.0001 vs the control group.